Treatment of focal anaplastic Wilms tumor: A report from the Children's Oncology Group AREN0321 and AREN03B2 studies
Cancer · 2025
DOI: 10.1002/cncr.35713 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Amy E Armstrong und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Hematology/Oncology, Washington University School of Medicine, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Wilms Tumor, Antineoplastic Combined Chemotherapy Protocols, Kidney Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, St. Baldrick's Foundation, National Cancer Institute's National Clinical Trial Network (NCTN) Operations Center.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
In the fifth National Wilms Tumor Study, patients received vincristine and dactinomycin (VA) without radiation for stage I focal anaplastic Wilms tumor (FAWT) and VA plus doxorubicin (DD4A) and radiation for stage II–IV FAWT. Four‐year event‐free survival (EFS) and overall survival (OS) for stage I FAWT were 67.5% and 88.9% and for stage IV FAWT were 61.4% and 71.6%, respectively. Therapy intensification for stage I and IV FAWT was evaluated as secondary objectives in AREN0321.
Methods
Central review in the AREN03B2 Renal Tumors Classification, Biology, and Banking Study confirmed patient stage and tumor histology. Patients were then enrolled in AREN0321 and received DD4A with radiation for stage I–III FAWT and vincristine, doxorubicin, cyclophosphamide, carboplatin, and etoposide (UH‐1/revised UH‐1) with radiation for stage IV FAWT. Outcomes of patients with FAWT who were treated in AREN0321 ( n = 25) and in AREN03B2 ( n = 20) treated as per AREN0321 were analyzed.
Results
In the pooled data analysis from AREN0321 and AREN03B2, 4‐year EFS and OS were both 100% for stage I–II FAWT ( n = 21), 82.4% (95% CI, 66.1%–100%) and 87.8% (95% CI, 73.4%–100%) for stage III FAWT ( n = 17), respectively, and both 85.7% (95% CI, 63.3%–100%) for stage IV FAWT ( n = 7). Four patients enrolled in AREN0321 had events: treatment failure occurred in three patients with stage III FAWT, and one treatment‐related death was observed in a patient with stage IV FAWT following revised UH‐1. No EFS or OS events occurred in patients with FAWT enrolled in AREN03B2 only.
Conclusions
Patients with stage I and II FAWT have outstanding survival when treated with DD4A and radiation. Intensification of therapy may have improved survival for stage IV FAWT, albeit with an increased toxicity risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Hematology/Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
- Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Division of Biostatistics, University of Southern California, Los Angeles, California, USA.
- Division of Oncology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA.
- Department of Radiation Oncology, Northwestern University, Chicago, Illinois, USA.
- Department of Radiology and Imaging Sciences, Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
ORCID-Profile: Amy E Armstrong, James I Geller, Arnold C Paulino, Elizabeth J Perlman, Peter F Ehrlich, Paul E Grundy
Förderung
- NCI NIH HHS
- St. Baldrick's Foundation
- National Cancer Institute's National Clinical Trial Network (NCTN) Operations Center
- Children's Oncology Group Chair's Grant
- Human Specimen Banking in National Cancer Institute-Sponsored Clinical Trials
- Children's Oncology Group NCTN Statistics & Data Center
- National Cancer Institute Clinician Scientist Research Specialist Award
Zitieren
APA
Armstrong, A. E., Daw, N. C., Renfro, L. A., Geller, J. I., Kalapurakal, J. A., Khanna, G., Paulino, A. C., Perlman, E. J., Ehrlich, P. F., Gow, K. W., Warwick, A. B., Grundy, P. E., Fernandez, C. V., Mullen, E. A., Dome, J. S., & Children's Oncology Group AREN0321 and AREN03B2 Study Committees (2025). Treatment of focal anaplastic Wilms tumor: A report from the Children's Oncology Group AREN0321 and AREN03B2 studies. Cancer. https://doi.org/10.1002/cncr.35713
Vancouver
Armstrong AE, Daw NC, Renfro LA, Geller JI, Kalapurakal JA, Khanna G, et al. Treatment of focal anaplastic Wilms tumor: A report from the Children's Oncology Group AREN0321 and AREN03B2 studies. Cancer. 2025. doi:10.1002/cncr.35713
BibTeX
@article{Armstrong2025,
author = {Armstrong, Amy E and Daw, Najat C and Renfro, Lindsay A and Geller, James I and Kalapurakal, John A and Khanna, Geetika and Paulino, Arnold C and Perlman, Elizabeth J and Ehrlich, Peter F and Gow, Kenneth W and Warwick, Anne B and Grundy, Paul E and Fernandez, Conrad V and Mullen, Elizabeth A and Dome, Jeffrey S and Children's Oncology Group AREN0321 and AREN03B2 Study Committees, Children's Oncology Group AREN0321 and AREN03B2 Study Committees},
title = {Treatment of focal anaplastic Wilms tumor: A report from the Children's Oncology Group AREN0321 and AREN03B2 studies},
journal = {Cancer},
year = {2025},
doi = {10.1002/cncr.35713}
}
EUVIMED